For example, targeting mTORC1 with rapamycin and AKT with MK2206 has been shown to increase radiation sensitivity in breast and non-small cell lung cancer models.523 Similarly, the dual PI3K‒mTOR inhibitor NVP-BEZ235 improved the response of glioblastoma cells to ionizing radiation.524 Finally, mTOR represents an attractive target for enhancing sensitivity to cisplatin, one of the mainstream chemotherapeutic agents.188. This evidence concerns the gene MTOR and non-small cell lung carcinoma.